ImmunityBio Inc. (IBRX): H.C. Wainwright Sees Potential for ANKTIVA in Therapy-Resistant Non-Muscle-Invasive Bladder Cancer
Reading Time: 2 minutes
ImmunityBio Inc. (IBRX) (i.) is a biotech company focused on developing next-generation therapies and vaccines that strengthen the natural immune system to combat cancer and infectious diseases. The company offers a range of immunotherapy and cell therapy platforms designed to generate a lasting and safe immune response against diseases. A key product in their pipeline is ANKTIVA (N-803), an IL-15 superagonist used in combination with other therapies for the treatment of various cancers. Other products in development include combinations such as...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
